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We investigated whether microRNA expression profiles can predict clinical outcome of NSCLC patients.
Using real-time RT-PCR, we obtained microRNA expressions in 112 NSCLC patients, which were divided
into the training and testing sets. Using Cox regression and risk-score analysis, we identified a five-microRNA
signature for the prediction of treatment outcome of NSCLC in the training set. This microRNA signature was
validated by the testing set and an independent cohort. Patients with high-risk scores in their microRNA sig-
natures had poor overall and disease-free survivals compared to the low-risk-score patients. This microRNA
signature is an independent predictor of the cancer relapse and survival of NSCLC patients.INTRODUCTION
Lung cancer, predominantly non-small-cell lung cancer (NSCLC),
is the most common cause of cancer deaths worldwide (Jemal48 Cancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc.et al., 2006). The relapse rate among patients with early-stage
NSCLC is 40% within 5 years after potentially curative treatment
(Miller, 2005). The current staging system for NSCLC is inade-
quate for predicting the outcome of treatment.SIGNIFICANCE
MicroRNAs are a class of small non-protein-coding RNAs that function in endogenous negative gene regulation and tumor-
igenesis. Lung cancer is the most common cause of cancer deaths worldwide. Current clinical-pathological staging
methods are inadequate to predict treatment outcome for lung cancer. We identified a five-microRNA signature that can
predict survival in lung cancer patients. This may have clinical implications in the molecular pathogenesis of cancer, devel-
opment of targeted therapy, or selection of high-risk cancer patients for adjuvant chemotherapy.
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of patients. Advances in genomics and proteomics have gener-
ated many candidate markers with potential clinical value (Lud-
wig and Weinstein, 2005). Gene expression profiling by microar-
ray or real-time RT-PCR can be useful in the classification or
prognosis of various types of cancer, including lung cancer
(Chen et al., 2007; Endoh et al., 2004; Potti et al., 2006). With
the advent of miRNA expression profiles, significant efforts
have been made to correlate miRNA expressions with tumor
prognosis (Calin and Croce, 2006a, 2006b; Cummins and Velcu-
lescu, 2006; Esquela-Kerscher and Slack, 2006; Garzon et al.,
2006; Gregory and Shiekhattar, 2005). Since one microRNA
can regulate hundreds of downstream genes, the information
gained from miRNA profiling may be complementary to that
from the expression profiling of protein-coding genes. Recent
reports even suggest that the expression profiling of microRNAs
may be a more accurate method of classifying cancer subtype
than using the expression profiles of protein-coding genes (Calin
and Croce, 2006b; Volinia et al., 2006).
MicroRNAs are a class of small non-protein-coding RNAs that
can act as endogenous RNA interference (Hammond, 2006).
MicroRNAs can posttranscriptionally regulate the expression of
hundreds of their target genes, thereby controlling a wide range
of biological functions such as cellular proliferation, differentia-
tion, and apoptosis (Calin and Croce, 2006b). Recent evidence
indicates that microRNAs may function as tumor suppressors
or oncogenes, and alteration in microRNA expression may play
a critical role in tumorigenesis and cancer progression (Calin
and Croce, 2006a; Esquela-Kerscher and Slack, 2006).
Our understanding of microRNA expression patterns as
potential biomarkers for diagnosis, prognosis, personalized ther-
apy, and disease management is just starting to emerge. Several
microRNAs were reported to be associated with the clinical
outcome of chronic lymphocytic leukemia (Calin et al., 2005),
lung adenocarcinoma (Takamizawa et al., 2004; Yanaihara
et al., 2006), and breast (Iorio et al., 2005) and pancreas (Bloom-
ston et al., 2007; Roldo et al., 2006) cancers. However, whether
a microRNA signature can predict clinical outcome of NSCLC,
including major histological or stage subgroups of NSCLC, is
not known.
To investigate this problem, we conducted an extensive
microRNA profiling study on a cohort of 112 NSCLC patients
from a hospital in central Taiwan. By the splitting-sample
approach, a five-microRNA signature was obtained from 56
patients for survival prediction and was validated on the other
56 patients. An independent cohort of 62 patients from a different
hospital, located in Northern Taiwan, was used to reconfirm the
effectiveness of this signature.
RESULTS
Detection of the Five-MicroRNA Signature
from the Training Set
The 112 specimens were randomly assigned to a training set (n =
56) or a testing set (n = 56). Only the training data set is used for
detection of the five-microRNA signature. We first applied the
Cox proportional hazard regression to each of the 157 micro-
RNAs for finding profiles that were correlated with the true overall
survival times (which can only be inferred statistically because ofheavy censoring). We identified five microRNAs that are signifi-
cantly associated with patient survival. We then used these
five significant microRNAs to construct a signature by the risk
score method. We found that two microRNAs (hsa-miR-221
and hsa-let-7a) were protective, and the other three microRNAs
(hsa-miR-137, hsa-miR-372, and hsa-miR-182*) were risky (see
Table S1 available online). A risk-score formula (see Experimen-
tal Procedures) was obtained for patient survival prediction.
Five-MicroRNA Signature and Patient Survival
in the Training Set
We used the risk-score formula and calculated the five-micro-
RNA signature risk scores for all patients in the training set. We
ranked patients in the training set according to their risk scores
and divided them into a high-risk group or low-risk group using
the median risk score as the cutoff point. Table 1 gives the clin-
ical characteristics of the 56 patients in the training set. Patients
with high-risk five-microRNA signature had shorter median over-
all survival than patients with low-risk microRNA signature
(20 months versus not reached, p < 0.001) (Figure 1A, left panel).
Patients with high-risk five-microRNA signature had shorter me-
dian relapse-free survival than patients with low-risk microRNA
signature (10 months versus not reached, p = 0.002) (Figure 1A,
right panel).
Validation of the Five-MicroRNA Signature
for Survival Prediction by the Testing Set
We used the same risk score formula obtained from the training
set and calculated the five-microRNA signature risk score for
each of the 56 patients in the testing set. We then classify them
into the high-risk group or low-risk group using the same cutoff
point as in the training set. Table 1 gives the clinical characteris-
tics of the 56 patients in the testing set. We carried out the same
survival comparison procedures as in the training set. Similar
to the findings from the training set, patients with high-risk
microRNA signature had shorter median overall survival than
patients with low-risk microRNA signature (25 months versus
not reached, p = 0.008) (Figure 1B, left panel). Likewise, patients
with high-risk microRNA signature had shorter median relapse-
free survival than patients with low-risk microRNA signature
(14 months versus not reached, p = 0.003) (Figure 1B, right panel).
We also showed the distribution of tumor microRNA expres-
sion, patient risk scores, and the survival status of 112 patients
(combination of the training and testing sets) (Figure 2). Tumors
with high risk scores tend to express risky microRNAs, whereas
tumors with low risk scores tend to express protective micro-
RNAs. Patients with high risk scores had more deaths than
low-risk-score patients. Similar results were found in both the
training set (Figure S1) and the testing set (Figure S2).
The entire microRNA data set is available in the Supplemental
Data.
Revalidation of the Five-MicroRNA Signature
for Survival Prediction by an Independent Cohort
To reconfirm our microRNA signature in an independent cohort,
we used 62 NSCLC patients from a different hospital, located in
northern Taiwan. Table 1 gives the clinical characteristics of the
62 patients in the independent cohort. Patients were classified
as high-risk or low-risk groups based on their microRNACancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc. 49
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MicroRNA Signature (%) p Value
Training data set (n = 56) n = 28 n = 28
Age (mean ± SD) 65.7 ± 10.3 67.3 ± 9.7 0.549a
Gender
Male 21 (75) 24 (86) 0.503b
Female 7 (25) 4 (14)
Stage
I 5 (18) 16 (57) 0.008b
II 8 (28) 6 (22)
III 15 (54) 6 (21)
Cell type
Adenocarcinoma 15 (54) 10 (36) 0.353b
Squamous cell carcinoma 10 (36) 15 (54)
Others 3 (10) 3 (10)
Testing data set (n = 56) n = 26 n = 30
Age (mean ± SD) 66.5 ± 13.6 64.3 ± 14.7 0.57a
Gender
Male 22 (85) 21 (70) 0.224b
Female 4 (15) 9 (30)
Stage
I 11 (42) 15 (50) 0.340b
II 5 (19) 9 (30)
III 10 (39) 6 (20)
Cell type
Adenocarcinoma 17 (65) 13 (43) 0.179b
Squamous cell carcinoma 9 (35) 16 (53)
Others 0 (0) 1 (4)
Independent cohort (n = 62) n = 40 n = 22
Age (mean ± SD) 62.9 ± 10.3 64.1 ± 9.1 0.634a
Gender
Male 32 (80) 10 (45) 0.010b
Female 8 (20) 12 (55)
Stage
I 15 (37) 13 (59) 0.152b
II 6 (15) 4 (18)
III 19 (48) 5 (23)
Cell type
Adenocarcinoma 21 (52) 9 (41) 0.563b
Squamous cell carcinoma 13 (33) 8 (36)
Others 6 (15) 5 (23)
a Student’s t test.
b Fisher’s exact test.signature risk scores. We found that patients with high-risk
microRNA signature had shorter median overall survival than
patients with low-risk microRNA signature (40 months versus
not reached, p = 0.007) (Figure 1C, left panel). Likewise, patients
with high-risk microRNA signature had shorter median relapse-
free survival than patients with low-risk microRNA signature
(20 months versus 48 months, p = 0.037) (Figure 1C, right panel).50 Cancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc.Multivariate Regression Analysis Shows
that the MicroRNA Signature Is Independent
from Stage or Histology
The multivariate Cox proportional hazard regression analysis and
stepwise variable selection were used to evaluate independent
prognostic factors associated with patient survivals in this inde-
pendent cohort of 62 NSCLC patients. The microRNA signature,
Cancer Cell
MiR Signature and Clinical Outcome of Lung Cancerage, sex, stage, and histology were used as covariates. Multivar-
iate regression analysis showed that the microRNA signature
(HR = 2.81, p = 0.026) and stage (HR = 2.35, p = 0.022) are inde-
pendent prognostic factors associated with overall survival or
disease-free survival of NSCLC patients and that the prognostic
ability of the microRNA signature is independent from stage or
histology (Table 2). Similar results were also found in the training
and the testing sets (see Table S2).
MicroRNA Signature Can Predict Patient Survivals
within Cancer Stages and Histological Subgroups
of NSCLC Patients
In order to investigate whether this microRNA signature can
distinguish high-risk versus low-risk groups of patients within
each stage stratum (NSCLC stage I, II, or III) and to predict their
survivals, we used the combined samples of the testing set and
the independent cohort for this analysis. From the survival curves
shown in Figure 3, we found that the high-risk survival curve lies
below the low-risk curve in all three stages.
We conducted a log-rank test for each stage. Unlike the
situation in the beginning, the two risk groups are introduced
and compared (Figure 1); the one-sided log-rank test makes bet-
ter sense here. The high-risk group defined before stratification
is expected to have a shorter survival time even after stratifica-
tion, and the low-risk group is expected to have a longer survival
time after stratification. We conducted the one-sided log-rank
Figure 1. Kaplan-Meier Estimates of Overall Survival and Relapse-
Free Survival of NSCLC Patients According to the MicroRNA Signa-
ture
(A) Fifty-six patients in the training data set.
(B) Fifty-six patients in the testing data set.
(C) Sixty-two patients in the independent cohort.test because the purpose of the test is not only to tell if the two
survival curves for the high-risk group and the low-risk group
are separable, but also to tell if the separation is in the correct
direction—namely, low-risk-signature patients have longer sur-
vival and high-risk-signature patients have shorter survival (Fig-
ures 3A–3C).
We found that the microRNA signature is significantly associ-
ated with relapse-free survival of patients with stage I disease
(p = 0.033). For the overall survival, the p value is 0.057, slightly
over the 5% level (Figure 3A). For stage II disease, the results are
marginal (p = 0.148, p = 0.095). This may be because the sample
size is too small (only 24 patients) to draw any firm conclusions
(Figure 3B). For stage III disease, the microRNA signature is
again significantly associated with the overall survival and re-
lapse-free survival of NSCLC patients (p = 0.0095, p = 0.044)
(Figure 3C).
Figure 2. MicroRNA Risk-Score Analysis of 112 NSCLC Patients
(Upper panel) MicroRNA risk-score distribution. (Middle panel) Patients’ sur-
vival status. (Bottom panel) Color-gram of microRNA expression profiles of
NSCLC patients; rows represent high-risk and protective microRNAs, and col-
umns represent patients. The blue dotted line represents the median micro-
RNA signature cutoff dividing patients into low-risk and high-risk groups.
Table 2. Multivariate Cox Regression* Analysis of the MicroRNA
Signature and Survivals in an Independent Cohort
Variable Hazard Ratio 95% CI p Value
Overall survival
MicroRNA expression signature 2.81 1.13–7.01 0.026
Stage 2.35 1.13–4.89 0.022
Relapse-free survival
MicroRNA expression signature 2.39 1.12–5.10 0.024
Stage 2.76 1.43–5.34 0.003
Age 0.93 0.90–0.97 <0.001
*Variables were selected through the stepwise selection method.Cancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc. 51
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microRNA signature is independent from stage, we conducted
the overall chi-square test that combines the three log-rank tests
together. The p value is 0.028 for the overall survival and 0.046
for the relapse-free survival (Table S3).
Next, we stratified the NSCLC patients by the histological
subtype of adenocarcinoma or squamous cell carcinoma. The
Figure 3. Kaplan-Meier Estimates of Overall Survival and Relapse-
Free Survival According to the MicroRNA Signature in Subgroups
of NSCLC Patients in the Combination of the Testing and Indepen-
dent Data Sets
(A) Stage I disease (n = 54).
(B) Stage II disease (n = 24).
(C) Stage III disease (n = 40).
(D) Adenocarcinoma patients (n = 60).
(E) Squamous cell carcinoma patients (n = 57).52 Cancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc.microRNA signature can predict patient survival within each
lung cancer histology subtype (Figures 3D and 3E). The overall
chi-square test that combines the two log-rank tests together
gives p values of 0.003 and 0.010 for overall survival and
relapse-free survival, respectively (Table S3).
All Five MicroRNAs Are Required in the Signature
To confirm that a set of five microRNAs is essential for this micro-
RNA signature, we constructed five competing four-microRNA
signatures by deleting one microRNA in turn from the set. We
then repeated the survival analysis for each of these ‘‘five-mi-
nus-one’’ microRNA signatures and compared the results with
the original five-microRNA signature using the log-rank analysis.
The results showed that, unlike the five-microRNA signature,
none of the ‘‘five-minus-one’’ microRNA signatures was consis-
tently correlated with overall survival and relapse-free survival
in the training data set, the testing data set, or the independent
cohort of NSCLC patients (Table S4).
Expression of MicroRNAs Alters Invasiveness
of Lung Cancer Cells
Two components of this five-microRNA signature, hsa-let-7a
and hsa-miR-372, can play opposite roles in tumorigenesis
through regulation of cell proliferation (Johnson et al., 2005;
Lee and Dutta, 2007; Mayr et al., 2007; Takamizawa et al.,
2004; Voorhoeve et al., 2006). In addition to cell growth, cell inva-
siveness is another key determinant of malignancy. However, the
association of microRNAs with cancer cell invasive ability is un-
known. To investigate the role of the five microRNAs in regulating
the invasiveness of cancer cells, we transfected each precursor
of high-risk microRNAs (hsa-miR-137, hsa-miR-182*, and hsa-
miR-372) into a low-invasive lung cancer cell line (CL1-0) and
each precursor of protective microRNAs (hsa-miR-221 and
hsa-let-7a) into a highly invasive lung cancer cell line (CL1-5).
The invasiveness of the transfectants was measured. We found
that the invasion ability of cancer cells to penetrate Matrigel
membrane was significantly increased by the three high-risk
microRNAs (hsa-miR-137, hsa-miR-182*, and hsa-miR-372)
and decreased by one protective microRNA (hsa-miR-221) com-
pared to control. Only hsa-let-7a did not affect the invasiveness
of lung cancer cells (Figure 4A).
Inorder toconfirmthat the fourmicroRNAscanalter the invasive
ability of cancer cells, we constructed microRNA expression vec-
tors that can produce these microRNAs driven by the CMV pro-
moter. The increased expression level of mature hsa-miR-137,
hsa-miR-182*, hsa-miR-372, and hsa-miR-221 was quantified
by real-time RT-PCR (Figure 4B). We confirmed that ectogenic
expression of hsa-miR-137, hsa-miR-182*, and hsa-miR-372
promoted invasiveness of lung cancer cell lines as compared
with parent cell control and mock negative control. We also con-
firmed that hsa-miR-221 inhibited cell invasion activity (Figure 4C).
DISCUSSION
In this study, we identified a five-microRNA signature (hsa-let-
7a, hsa-miR-221, hsa-miR-137, hsa-miR-372, and hsa-miR-
182*) that is associated with survival and cancer relapse in
NSCLC patients. We confirmed these findings in a testing set
and an independent cohort of NSCLC patients. Patients with
Cancer Cell
MiR Signature and Clinical Outcome of Lung Cancera high-risk score of this five-microRNA signature in their tumor
specimens had increased cancer relapse and shortened sur-
vival, even after stratifying patients by stage or histology (adeno-
carcinoma or squamous cell carcinoma) subgroups. These
results suggest that microRNAs may play an important role in
the molecular pathogenesis, clinical cancer progression, and
prognosis of NSCLC.
Figure 4. MicroRNA Expression Alters the Invasiveness of Lung
Cancer Cells In Vitro
(A) The effect of microRNAs on cancer cell invasiveness. The low invasive lung
cancer cell line (CL1-0) was transfected with high-risk microRNA precursors
(hsa-miR-137, hsa-miR-182*, or hsa-miR-372), and the high invasive cell line
(CL1-5) was transfected with protective microRNA precursors (hsa-miR-221
and hsa-let-7a). Twenty-four hours after transfection, cells were seeded onto
Transwell culture inserts and cultured for 18 hr. The invasive ability of trans-
fected cells was measured by modified Boyden chamber assay. The number
of invaded cells in cells transfected with negative control 1 precursor miRNA
acts as microRNA control (miR-con), and relative invasiveness of each micro-
RNA was normalized to miR-con. Each type of cell was assayed in quaternary.
(B) Ectogenic microRNA expression quantified by real-time RT-PCR. Quantifi-
cation of microRNA expression utilized total RNA isolated from cells transiently
transfected with microRNA expression vector. The expression of microRNA
was normalized to U6 RNA expression, and the microRNA transfectants
were normalized to parental cell control (CL1-0 or CL1-5). Each type of cells
was assayed in triplicate.
(C) The effect of microRNAs on invasiveness evaluated by using ectogenic
microRNA expression vectors. Invasion assay was performed as mentioned
in (A). The number of invaded cells in cells transfected with pSilencer4.1-
CMV puro negative control acts as microRNA control (miR-con). Each type
of cells was assayed in quaternary.
All data were processed by two-sided Student’s t test and presented as
mean ± SD. * p < 0.05.MicroRNAs are small noncoding RNAs that can function as
endogenous negative gene regulators, act as tumor suppressors
or oncogenes, and play important roles in cancer progression
(Calin and Croce, 2006b). Gene expression profiling using micro-
array or RT-PCR can be useful in the classification or prediction
of prognosis of NSCLC (Endoh et al., 2004; Potti et al., 2006).
Since each microRNA may regulate hundreds of downstream
genes, the information gained from microRNA profiling may be
complementary to the microarray gene expression profiling of
protein-coding genes. Lu et al. reported that microRNA profiles
are more effective in cancer classification than mRNA profiles
containing over 16,000 genes (Lu et al., 2005). Our knowledge
about the relationship between microRNA expression and clini-
cal outcome of patients is just emerging.
The presence of hsa-let-7a in this microRNA signature in this
NSCLC study is consistent with two recent reports that reduced
hsa-let-7a expression is associated with shortened survival
of lung adenocarcinoma patients (Takamizawa et al., 2004;
Yanaihara et al., 2006). On the other hand, the microRNA (hsa-
miR-155) reported to be associated with survival in lung adeno-
carcinoma patients by Yanaihara et al. was not included in our
microRNA signature (Yanaihara et al., 2006). In protein-coding
gene expression profiling, the genes associated with patient sur-
vival can vary substantially from study to study, with few genes
being consistently reported in different lung cancer studies
(Beer et al., 2002; Potti et al., 2006). For the microRNA profiling,
it remains uncertain whether the results between different stud-
ies may be equally inconsistent or not.
The identification of a microRNA signature that can predict
survival of patients with squamous cell carcinoma or adenocar-
cinoma is an important finding. It suggests that microRNAs may
have an important role in the enhancement of cancer progres-
sion for a broad spectrum of NSCLC, thus indicating a wide
clinical applicability.
The current clinical-pathological staging method has limited
success in predicting patient survival. For patients with identical
clinical-pathological characteristics or the same stage of lung
cancer, great uncertainties remain regarding how some patients
will be cured while other patients will have cancer recurrence,
metastasis, or death after surgical resection. Applying our five-
microRNA signature to the combined samples of the testing
set and the independent cohort, in all stages, we found a clear
separation between the low- and the high-risk curves in the
time range that is clinically most relevant. For instance, at stage
III, consider the relapse-free survival time at 36 months. Our data
show that a survival probability of 36 months is 0.43 for the low-
risk microRNA signature group and is 0.22 for the high-risk sig-
nature. The results of chi-square testing showed that the five-
microRNA signature is independent of stage or histology types
(Table S3). When the subgroup stratified analysis was performed
to test the independence of the signature, we found a pattern of
persistently small p values. Separately, because of the small
sample sizes, two of them (overall and relapse-free survivals of
patients with stage II) are only marginally significant. However,
combining all tests together, the overall p values do reach statis-
tical significance.
We showed that the five-microRNA signature can distinguish
high-risk versus low-risk patients within stage subgroups. This
finding may potentially enable doctors to identify and selectCancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc. 53
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standard surgery in order to improve the treatment outcome of
NSCLC. Cisplatin-based adjuvant chemotherapy was recently
reported to be effective for improvement of survival of NSCLC
patients after surgical resection (The International Adjuvant
Lung Cancer Trial Collaborative Group, 2004). The report that
gene expression (ERCC1) can predict NSCLC patients’ response
to cisplatin-based adjuvant chemotherapy was also recently
reported (Olaussen et al., 2006).
Because there are still possibilities of false positives in selec-
tion of the five-miRNAs for the prediction of clinical outcome,
we further validated our findings using an independent cohort
of lung cancer patients. The validity of a gene signature as a pre-
dictor of clinical outcome lies in the internal validation (the training
set and the testing set), the external validation (in an independent
cohort), and validity across different subgroups (cancer stages
and cell types) of patients (Simon et al., 2003). This five-micro-
RNA signature may have satisfied these criteria. Our finding
that this five-microRNA signature can predict high-risk and
low-risk patients within stage subgroups of NSCLC patients is
an important finding that may add supportive evidence that
microRNAs may play an important prognostic role in NSCLC
patients. In fact, the results of predictor power generated from
microRNA or mRNA signatures had been reported in the litera-
ture (Beer et al., 2002; Bloomston et al., 2007; Calin et al.,
2005; Chen et al., 2007; Endoh et al., 2004; Lossos et al., 2004;
Potti et al., 2006; Yanaihara et al., 2006). They showed good per-
formance in survival prediction. Our five-microRNA signature not
only predicted overall survival and predicted relapse-free survival
well across three data sets (the training, testing, and independent
sets) but also showed good predictive power in overall survival
and relapse-free survival using a real-time RT-PCR assay.
Determination of microRNA signature inpatientsusing real-time
RT-PCR and assessing a small number of microRNAs as in this
study may be a clinically applicable procedure. This is because
it gives accurate and reproducible RNA quantification results
from small amount of bronchoscopy sampling or paraffin-embed-
ded specimens (Bast and Hortobagyi, 2004; Ramaswamy, 2004).
In contrast, the reproducibility of hybridization-based microarray
technologies is still questionable, and frozen fresh tissues are
usually needed in the assay (Jiang et al., 2005; Lu et al., 2005;
Tang et al., 2006).
The five microRNAs identified in this study that can predict
clinical outcome of NSCLC may generate potential molecular
targets for the development of anticancer therapy (Czech,
2006). hsa-let-7a is a protective microRNA that suppresses
RAS and other transcription factors, and hsa-let-7a expression
is associated with prolonged survival in NSCLC patients (Gros-
shans et al., 2005; Johnson et al., 2005; Takamizawa et al.,
2004). In addition, recently evidence demonstrated that hsa-
let-7a inhibits cell proliferation and anchorage-independent
growth through repression of the HMGA2 oncogene (Lee and
Dutta, 2007; Mayr et al., 2007). hsa-miR-221 is another protec-
tive microRNA that inhibits erythroleukemic cell growth and an-
giogenesis via kit receptor downmodulation, suggesting a possi-
ble role for miR-221 at least as a modulator of the formation of
vessels in tumor microenvironment (Felli et al., 2005; Poliseno
et al., 2006). However, a recent report suggested that hsa-
miR-221 directly targets tumor suppressor p27Kip1 to cause54 Cancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc.the acceleration of cell cycle in prostate cancer cells (Galardi
et al., 2007). It is well known that one microRNA can regulate
many targets. Therefore, it may be possible that the same micro-
RNA may play opposite roles in cancer progression, both as a tu-
mor suppressor in certain cancers and as an oncogene in others.
Regarding the potential role of the three risky microRNAs in
this microRNA signature, hsa-miR-372 was reported to act as
an oncogene in testicular germ cell tumors by downregulating
the tumor suppressor LATS2 (Voorhoeve et al., 2006). To our
best knowledge, the molecular mechanism of hsa-miR-137
and hsa-miR-182* in cancer biology has not been reported yet.
Two components of this five-microRNA signature, hsa-let-7a
and hsa-miR-372, can play opposite roles in tumorigenesis
through regulation of cell proliferation (Johnson et al., 2005;
Lee and Dutta, 2007; Mayr et al., 2007; Takamizawa et al.,
2004; Voorhoeve et al., 2006). In addition to cell growth, cell in-
vasiveness is another key determinant of malignancy. However,
the association of microRNAs with cancer cell invasive ability is
unknown. We found that the risky microRNAs (hsa-miR-137,
hsa-miR-182*, and hsa-miR-372) promote the invasive ability
of lung cancer cells and the protective microRNA (hsa-miR-
221) inhibits cancer cell invasiveness. A somewhat unexpected
finding is that hsa-let-7a does not lower the invasiveness of the
more invasive lung cancer cell line. This suggests that the can-
cer-protective effect of hsa-let-7a may come from suppression
of cell proliferation (Johnson et al., 2005; Mayr et al., 2007; Taka-
mizawa et al., 2004). Further investigation of the regulatory mech-
anism of these microRNAs and their interactions may increase
our understanding of the molecular pathogenesis of NSCLC.
In conclusion, the five-microRNA signature can predict cancer
recurrence and survival of NSCLC patients. This may have prog-
nostic or therapeutic implications for the future management of
NSCLC patients.
EXPERIMENTAL PROCEDURES
Patients and Tissue Specimens
We studied frozen specimens of lung cancer tissue from 112 consecutive
patients who underwent surgical resection of NSCLC at the Taichung Veterans
General Hospital between September 2000 and December 2003. The patients
had not received adjuvant chemotherapy. We validated the microRNA signa-
ture using an independent cohort of 62 consecutive patients who underwent
surgical resection of NSCLC at the National Taiwan University Hospital
between February 1995 and December 2001.This study was approved by
the Institutional Review Boards of the Hospitals. Written informed consent
was obtained from all patients.
MicroRNA Profiling
MicroRNA expression profiling was performed using ABI PRISM 7900 Real
Time PCR System and TaqMan MicroRNA Assays Human Panel-Early Access
Kit containing 157 mature human microRNAs (Applied Biosystems, Foster
City, CA). The cDNA was made using TaqMan MicroRNA RT reagent and spe-
cific primers for each microRNA. The transcripts were amplified with reagent
(TaqMan 2x Universal PCR Master mix). MicroRNA expression was quantified
in relation to the expression of small nuclear U6 RNA. The U6 RNA is a common
internal control for microRNA quantification assays (Jiang et al., 2005; Yanai-
hara et al., 2006). Only five microRNAs are measured in the independent
cohort because we only need five microRNAs to produce the signature.
Statistical Analysis
The 112 specimens were randomly assigned to a training data set (n = 56)
or a testing data set (n = 56). The expression level of each microRNA was
Cancer Cell
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identify which microRNAs were associated with death from recurrence of can-
cer or any cause. Protective microRNAs were defined as those with hazard
ratio for death < 1. High-risk microRNAs were defined as those with hazard ra-
tio for death > 1. In most clinical studies, heavy censor rates higher than 60%
are typical. For example, the censoring rate for our study is 66%, and that for
the study reported by Beer et al. (2002) is 72%. Censoring refers to the patients
who may drop out or still are alive at the end of the study. If we divide the
patients into long overall survival and short overall survival according to the
survival time being longer than 24 months or not, we will end up with 24 patients
in the long survival group and 16 patients in the short survival group in the train-
ing data set. The other patients cannot be placed in either group because we
don’t know their actual survival time. In fact, leaving censored patients out
would introduce bias to the remaining uncensored samples, and it is difficult
to make adjustment for such bias. The approach we use, Cox proportional
hazard regression (Cox, 1972), is a standard method in biostatistics for dealing
with survival data.
The permutation test procedure is described in the section ‘‘MicroRNA
selection from the training set’’ of the Supplemental Experimental Procedures.
We found 5 out of 157 microRNAs that are significantly associated with the pa-
tient survival by Cox proportional hazard regression in the training data set. To
investigate the effectiveness of these five microRNAs as a microRNA-based
gene signature for clinical outcome prediction, a mathematical formula for
survival prediction was constructed, taking into account both the strength
and the positive or negative association of each microRNA with survival.
More specifically, we assigned each patient a risk score according to a linear
combination of the expression level of the microRNAs, weighted by the regres-
sion coefficients derived from the aforementioned univariate Cox regression
analyses (Lossos et al., 2004). From our five-microRNA signature, the risk
score for each patient was calculated as follows:
Risk-score = (0.153 expression level of hsa-miR-137) + (0.313 expression
level of hsa-miR-372) + (0.28 3 expression level of hsa-miR-182*) + (0.13 3
expression level of hsa-miR-221) + (0.14 3 expression level of hsa-let-7a).
Patients having higher risk scores are expected to have poor survival
outcomes.
We divided patients in the training data set into high-risk and low-risk groups
using the median microRNA signature risk score as the cut-off point. The
difference in patient characteristics between the high-risk and the low-risk
groups was analyzed using Student’s t test for continuous variables or using
Fisher’s exact test for categorical variables. The Kaplan-Meier method was
used to estimate overall survival and relapse-free survival. Differences in
survival between high-risk and the low-risk patients were analyzed using the
two-sided log-rank test.
According to Simon et al. (2003), there are at least two ways of validation:
internal validation (splitting sample or crossvalidation) versus external valida-
tion. The splitting-sample strategy is to separate patients into a training set
and a testing set. First, the classifier genes are selected based on data from
the training set and are validated with data from the testing cohort. There is
no overlap between the two sets, which is an advantage over crossvalidation.
The generalization ability of the statistical procedures from the training set to
other data can be more faithfully examined.
Simon et al. suggested that the splitting-sample method appears to be a bet-
ter choice than the repeated random partition method and crossvalidation if
the sample size is not too small.
In internal validation, the training and the testing samples are taken from the
same population. Because it is important to examine how well the detected
biomarkers will perform in other populations, Simon et al. urged for an external
validation in which additional independent samples should be taken. Conform-
ing with their suggestions, the samples used in our external validation come
from a different medical center. We validated the performance of our micro-
RNA signature risk-score model using patients in the testing data set and
the independent cohort of NSCLC.
We employed two statistical approaches to investigate whether the micro-
RNA signature is an independent predictor of overall survival and disease-
free survival in NSCLC patients, especially whether it is independent of stage.
The starting approach is multivariate Cox regression analysis. In the Cox
regression, the stepwise selection method is performed to select the optimal
combination of variables. The concept of multivariate analysis is that the esti-mated hazard ratio of our five-microRNA signature is adjusted by the effects of
potential confounding variables (e.g., stage). On the other hand, if the con-
founders are controlled in the multivariate model, the effect of our microRNA
signature is an independent prognostic factor. The multivariate Cox propor-
tional hazard regression analysis and stepwise variable selection were used
to evaluate the contribution of independent prognostic factors to patient
survival. The microRNA signature risk score, age, sex, stage, and histology
were used as covariates. All analyses were done with SAS version 9.1 software
(SAS Institute Inc). Two-tailed tests and p values < 0.05 for significance were
used.
The second approach is the use of stage stratification and histology stratifi-
cation to avoid the confounding effect of stage and histology. We stratified
patients by stage (NSCLC stage I, II, or III) and by histology (adenocarcinoma
or squamous cell carcinoma) and then performed Kaplan-Meier estimates of
overall survival and relapse-free survival of patients according to their high-
risk or low-risk microRNA signature. Survivals were compared using the
one-sided log-rank test. The one-sided test may be appropriate here because
the hypothesis we wish to test is the one-sided hypothesis that the survival
time is longer for patients with the low-risk microRNA signature than that for
patients with the high-risk signature, not the two-sided hypothesis that the
survival time is different between the low-risk signature and high-risk signature
(Green et al., 2003; Koch and Gillings, 1988).
To seek statistical evidence for supporting the one-sided hypothesis that the
high risk score of microRNA signature can predict poor survival in NSCLC
patients, the combined samples of testing set and independent cohort were
analyzed with the one-sided log-rank test (Flanigan et al., 2001; Seymour
et al., 2007).
To test if the signature is independent from the stage, we use chi-square dis-
tribution of three degrees of freedom to find the p value for combining the three
log-rank tests from stage stratification. The degree of freedom is two for com-
bining the two log-rank tests from histology stratification (see Supplemental
Experimental Procedures for details).
Cell Culture and Transfection
The human lung adenocarcinoma cell lines CL1-0 and CL1-5 were established
in a previous study in which the invasive competence of CL1-5 is higher than
that of CL1-0 (Chen et al., 2001). Cells were cultured in DMEM medium
(GIBCO, Grand Island, NY) with 10% fetal bovine serum.
All of the following partially double-stranded RNAs that mimic endogenous
precursor miRNAs were purchased from Ambion (Ambion, Austin, TX): hsa-
miR-137, hsa-miR-182*, hsa-miR-221, hsa-miR-372, hsa-let-7a, and negative
control 1 precursor miRNAs. They were transfected into cells at final concen-
trations of 100 nM each using Oligofectamine (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instruction. Twenty-four hours after transfec-
tion, the invasiveness of cells was analyzed.
To transiently express microRNAs, paired oligonucleotides based on the
precursor sequences of hsa-miR-137, hsa-miR-182*, hsa-miR-221, and hsa-
miR-372 (http://microrna.sanger.ac.uk/) were cloned into the BamHI and
HindIII sites of an expression vector pSilencer4.1-CMV puro (Ambion, Austin,
TX). The pSilencer4.1-CMV puro Negative Control is a negative control plas-
mid encoding a hairpin siRNA whose sequence is not found in the human
genome databases (Ambion, Austin, TX).
Invasion Assay
Transwell culture inserts with their companion 24-well plates (Costar, Cam-
bridge, MA) were used for the assessment of cell migration and extracellular
matrix invasion as described previously with slight modification (Shridhar
et al., 2004). Briefly, the culture inserts consist of an 8 mm pore-size polycar-
bonate filter upon which cells can be seeded and grown. The filters were
coated with appropriate Matrigel (Becton Dickinson, Bedford, MA). Appro-
priate number of transfected cells (1 3 105 for CL1-0 and 1 3 104 for
CL1-5) were seeded onto the Matrigel and incubated for 18 hr. The filters
coated with Matrigel were swabbed with a cotton swab, fixed with methanol,
and then stained with Giemsa solution. The number of cells attached to
the lower surface of the polycarbonate filter was totally counted at 2003
magnification under a light microscope. Each type of cell was assayed in
quaternary.Cancer Cell 13, 48–57, January 2008 ª2008 Elsevier Inc. 55
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